Treatment with selective estrogen receptor modulators regulates myelin specific T‐cells and suppresses experimental autoimmune encephalomyelitis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Steroidal estrogens can regulate inflammatory immune responses and may be involved in the suppression of multiple sclerosis (MS) during pregnancy. However, the risks and side effects associated with steroidal estrogens may limit their usefulness for long‐term MS therapy. Selective estrogen receptor modulators (SERMs) could provide an alternative therapeutic strategy, because they behave as estrogen agonists in some tissues, but are either inert or behave like estrogen antagonists in other tissues. In this study, we investigated the ability of two commercially available SERMs (tamoxifen and raloxifene) to regulate myelin specific immunity and experimental autoimmune encephalomyelitis (EAE) in mice. Both tamoxifen and raloxifene suppressed myelin antigen specific T‐cell proliferation. However, tamoxifen was more effective in this regard. Tamoxifen treatment reduced the induction of major histocompatibility complex II by lipopolysaccharide stimulated dendritic cells and decreased their ability to activate myelin specific T‐cells. At lower doses, tamoxifen was found to increase the levels of Th2 transcription factors and induce a Th2 bias in cultures of myelin‐specific splenocytes. EAE symptoms and the degree of demyelination were less severe in mice treated with tamoxifen than in control mice. These findings support the notion that tamoxifen or related SERMs are potential agents that could be used in the treatment of inflammatory autoimmune disorders that affect the central nervous system. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 5×
“…not Increase the Frequency of Treg Cells in Mice with EAE Treg cells include different functional and phenotypic subpopulations and are characterized by a number of markers including CD4, CD25, CTLA-4, and FoxP3 (Fontenot et al., 2003; Sakaguchi, 2005; Sansom and Walker, 2006; Tang et al., 2004).”
BackgroundInfluentialRate of Pregnancy-Related Relapse in Multiple Sclerosis
Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390501 · Cited by 1,559
Treatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435
Estriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis
Kim, S., Liva, S. M., Dalal, M. A., Verity, M. A., & Voskuhl, R. R. (1999) · Neurology · doi:10.1212/wnl.52.6.1230 · Cited by 268
Lambert, K. C., Curran, E. M., Judy, B. M., Milligan, G. N., Lubahn, D. B., & Estes, D. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5716 · Cited by 142 · cited 1×
“There is evidence that CD41 T-cells express both ER-a and ER-b (Kassi et al., 2001; Lambert et al., 2005; Liu et al., 2003; Phiel et al., 2005) and some effects of estrogen treatment can be ascribed to a direct interaction with CD41 T-cells (Lambert et al., 2005).”
Background
Cited by
The neuroprotective actions of oestradiol and oestrogen receptors
Arevalo, M.-A., Azcoitia, I., & Garcia-Segura, L. M. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3856 · Cited by 480
Estrogen Receptor Signaling in the Immune System
Chakraborty, B., Byemerwa, J., Krebs, T., Lim, F., Chang, C.-Y., & McDonnell, D. P. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 263
Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration
Spence, R. D., & Voskuhl, R. R. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.12.001 · Cited by 258
Retinal microglia initiate neuroinflammation in ocular autoimmunity
Okunuki, Y., Mukai, R., Nakao, T., Tabor, S. J., Butovsky, O., Dana, R., Ksander, B. R., & Connor, K. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820387116 · Cited by 216
Actions of estrogens on glial cells: Implications for neuroprotection
Arevalo, M.-A., Santos-Galindo, M., Bellini, M.-J., Azcoitia, I., & Garcia-Segura, L. M. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.10.002 · Cited by 214
A new genetic strategy for targeting microglia in development and disease
McKinsey, G. L., Lizama, C. O., Keown-Lang, A. E., Niu, A., Santander, N., Larpthaveesarp, A., Chee, E., Gonzalez, F. F., & Arnold, T. D. (2020) · eLife · doi:10.7554/elife.54590 · Cited by 176
“Tamoxifen-dependent effects on neuroinflammation will be important to control for if this strategy is used (Bebo et al., 2009).”
BackgroundThe Effects of Tamoxifen on Immunity
Behjati, S., & Frank, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803042 · Cited by 116
Tamoxifen promotes differentiation of oligodendrocyte progenitors in vitro
Barratt, H. E., Budnick, H. C., Parra, R., Lolley, R. J., Perry, C. N., & Nesic, O. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.026 · Cited by 22
“Neuroprotective effects of TMX have also been demonstrated in a number of other demyelinating conditions, such as multiple sclerosis (Bebo et al., 2009), traumatic injury to the central and peripheral nervous system, and stroke (Arevalo et al., 2011), although the underlying mechanism responsible…”
Background
Metadata
- Authors
- Bebo, B. F., Dehghani, B., Foster, S., Kurniawan, A., Lopez, F. J., & Sherman, L. S.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2008-11-20
- Volume
- 57
- Issue
- 7
- Pages
- 777-790
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2048944834
- Cited by
- 71
- References
- 5
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.